AR127582A1 - METHODS FOR THE TREATMENT OF CANCER - Google Patents
METHODS FOR THE TREATMENT OF CANCERInfo
- Publication number
- AR127582A1 AR127582A1 ARP220103034A ARP220103034A AR127582A1 AR 127582 A1 AR127582 A1 AR 127582A1 AR P220103034 A ARP220103034 A AR P220103034A AR P220103034 A ARP220103034 A AR P220103034A AR 127582 A1 AR127582 A1 AR 127582A1
- Authority
- AR
- Argentina
- Prior art keywords
- salt
- compound
- treatment
- cancer
- suppression
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 10
- 150000003839 salts Chemical class 0.000 abstract 9
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 230000001629 suppression Effects 0.000 abstract 4
- 239000003937 drug carrier Substances 0.000 abstract 1
- 102200006538 rs121913530 Human genes 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción proporciona compuestos y métodos útiles para el tratamiento y la supresión del cáncer, por ejemplo, útiles para el tratamiento o la supresión de cánceres caracterizados por KRAS G12C. También se proporcionan composiciones farmacéuticas que contienen estos compuestos y procesos para la preparación de estos compuestos. Un compuesto de la fórmula (1) o la fórmula (2). Reivindicación 111: Una formulación farmacéutica que comprende el compuesto de cualquiera de las reivindicaciones 1 - 109, donde, cuando el compuesto es una sal, la sal es una sal farmacéuticamente aceptable, y un portador farmacéuticamente aceptable. Reivindicación 112: Un método para el tratamiento o la supresión del cáncer que comprende: administrarle a un sujeto que lo necesite una cantidad terapéuticamente eficaz de un compuesto de cualquiera de las reivindicaciones 1 - 109, donde, cuando el compuesto es una sal, la sal es una sal farmacéuticamente aceptable, o una formulación farmacéutica de acuerdo con la reivindicación 111. Reivindicación 113: Un compuesto de cualquiera de las reivindicaciones 1 - 109 o una formulación farmacéutica de acuerdo con la reivindicación 111 para utilizar en el tratamiento o la supresión del cáncer, donde, cuando el compuesto es una sal, la sal es una sal farmacéuticamente aceptable.The present disclosure provides compounds and methods useful for the treatment and suppression of cancer, for example, useful for the treatment or suppression of cancers characterized by KRAS G12C. Also provided are pharmaceutical compositions containing these compounds and processes for the preparation of these compounds. A compound of formula (1) or formula (2). Claim 111: A pharmaceutical formulation comprising the compound of any of claims 1 - 109, wherein, when the compound is a salt, the salt is a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier. Claim 112: A method for the treatment or suppression of cancer comprising: administering to a subject in need thereof a therapeutically effective amount of a compound of any of claims 1 - 109, wherein, when the compound is a salt, the salt is a pharmaceutically acceptable salt, or a pharmaceutical formulation according to claim 111. Claim 113: A compound of any of claims 1 - 109 or a pharmaceutical formulation according to claim 111 for use in the treatment or suppression of cancer , where, when the compound is a salt, the salt is a pharmaceutically acceptable salt.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063356906P | 2020-06-29 | 2020-06-29 | |
| US202063403565P | 2020-09-02 | 2020-09-02 | |
| US202163276478P | 2021-11-05 | 2021-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127582A1 true AR127582A1 (en) | 2024-02-07 |
Family
ID=90220616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103034A AR127582A1 (en) | 2020-06-29 | 2022-11-04 | METHODS FOR THE TREATMENT OF CANCER |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR127582A1 (en) |
-
2022
- 2022-11-04 AR ARP220103034A patent/AR127582A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000167A1 (en) | Functionalized peptides as antiviral agents | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| MA40111B1 (en) | Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein | |
| RU2013121788A (en) | HIV REPLICATION INHIBITORS | |
| RU94044677A (en) | Trisubstituted phenyl-derivatives, method of synthesis, pharmaceutical composition | |
| MX2021010106A (en) | Inhibitors of integrated stress response pathway. | |
| UY39529A (en) | NEW ANTIVIRAL AGENTS DERIVED FROM SPIROPYRROLIDINE | |
| DOP2020000058A (en) | CHROMAN MONOBACTAMIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| EA202092168A1 (en) | APPLICATION OF FAVIPIRAVIR IN THE TREATMENT OF CORONAVIRUS INFECTION | |
| CO2023002852A2 (en) | Functionalized peptides as antiviral agents | |
| MX2022000390A (en) | Macrocyclic spirocycle derivatives as mcl-1 inhibitors. | |
| EA201992090A1 (en) | Deuterated Imidazo [4,5-c] Quinolin-2-One Compounds and Their Use in Cancer Treatment | |
| MX2022015813A (en) | Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1. | |
| AR007021A1 (en) | DERIVATIVES OF 3-DESCLADINOSA-2,3-ANHIDROERITROMICINA, PROCEDURES FOR ITS PREPARATION, COMPOUNDS FOR ITS EXCLUSIVE USE IN SUCH PROCEDURES AND PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION TO TREAT BACTERIAL INFECTIONS AND THE USE OF THESE COMPUTERS | |
| CO2019004004A2 (en) | Pharmaceutical composition and method for the treatment of non-alcoholic fatty liver disease | |
| MX2022015554A (en) | Small molecule modulators of il-17. | |
| EA201991069A1 (en) | COMBINED THERAPY INHIBITOR OF PHOSPHOINOSITIDE-3-KINASE AND BINDING ZINC AGENT | |
| MX2022003845A (en) | Medicinal cognitive treatments. | |
| AR127582A1 (en) | METHODS FOR THE TREATMENT OF CANCER | |
| AR127247A1 (en) | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | |
| MX2023003576A (en) | Compound as akt kinase inhibitor. | |
| PH12021550471A1 (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| MX2022011242A (en) | Immunomodulating o-het-aryl azalides. | |
| MX2022013890A (en) | Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof. | |
| MX2021008658A (en) | Solid forms of ttk inhibitor. |